Acalabrutinib was approved by the U.S. Food and Drug Administration (FDA) on October 31, 2017 [1]. This approval was for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [1].
What is Acalabrutinib?
Acalabrutinib, marketed as Calquence, is a targeted therapy medication that works by inhibiting Bruton's tyrosine kinase (BTK) [2]. BTK is a protein that plays a crucial role in the growth and survival of certain types of B-cells, including those involved in MCL [3]. By blocking BTK, acalabrutinib can help to stop the proliferation of these cancer cells [3].
What are the FDA-approved uses for Acalabrutinib?
Following its initial approval for MCL, acalabrutinib later received FDA approval for additional indications. These include the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [2]. It is also approved for adults with previously treated CLL/SLL and for previously untreated CLL/SLL [2].
When does Acalabrutinib's patent expire?
Patent expiry dates for drugs are complex and can involve multiple patents covering different aspects of the drug. According to DrugPatentWatch.com, there are various patents associated with acalabrutinib, with some expiring in the mid-2030s, while others extend further [4]. The exact date of market exclusivity for acalabrutinib can depend on patent litigation and the specific markets [4].
Who manufactures Acalabrutinib?
Acalabrutinib is manufactured by AstraZeneca [2].
What are the key clinical trial results for Acalabrutinib?
The initial FDA approval for acalabrutinib in MCL was based on a single-arm clinical trial that demonstrated a high overall response rate [1]. Subsequent trials have further evaluated its efficacy and safety in MCL, CLL, and SLL, comparing it to existing treatments [5][6]. For instance, studies have shown its effectiveness in both previously treated and untreated patients with CLL/SLL [5][6].
What are the potential side effects of Acalabrutinib?
Common side effects associated with acalabrutinib include diarrhea, fatigue, headache, muscle pain, and bruising [2]. More serious potential side effects can involve an increased risk of infections, bleeding events, cardiac events such as atrial fibrillation, and new or worsening hypertension [2].
Can generic or biosimilar versions of Acalabrutinib become available?
The availability of generic versions of small molecule drugs like acalabrutinib is contingent upon patent expiry and the successful navigation of regulatory pathways, such as demonstrating bioequivalence. The timeline for generic entry depends on the patents that remain in force and any potential challenges to those patents [4].
How does Acalabrutinib compare to other BTK inhibitors?
Acalabrutinib is one of several BTK inhibitors available for treating B-cell malignancies. Other notable BTK inhibitors include ibrutinib and zanubrutinib. These drugs share a similar mechanism of action but may differ in their selectivity for BTK, their pharmacokinetic profiles, and their side effect profiles [7]. Comparative studies help to distinguish the specific benefits and risks of each agent [7].
What are the regulatory hurdles for new cancer drugs like Acalabrutinib?
The FDA approval process for new cancer drugs involves rigorous evaluation of clinical trial data to establish safety and efficacy [8]. This includes assessing the drug's ability to improve patient outcomes, such as progression-free survival or overall survival, and managing potential toxicities [8].
---
Sources:
[1] U.S. Food and Drug Administration. (2017, October 31). FDA approves Calquence (acalabrutinib) for mantle cell lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-calquence-acalabrutinib-mantle-cell-lymphoma
[2] National Cancer Institute. (n.d.). Acalabrutinib. Retrieved from https://www.cancer.gov/drug-information/drug-names/acalabrutinib
[3] National Cancer Institute. (n.d.). Bruton's tyrosine kinase inhibitors. Retrieved from https://www.cancer.gov/about-cancer/treatment/types/drug-therapy/btk-inhibitors
[4] DrugPatentWatch.com. (n.d.). Acalabrutinib Patents. Retrieved from https://drugpatentwatch.com/acalabrutinib
[5] Byrd, J. C., et al. (2019). Acalabrutinib versus rituximab plus chemotherapy in previously untreated chronic lymphocytic leukemia. New England Journal of Medicine, 380(6), 526-537.
[6] Ghose, A., et al. (2021). Acalabrutinib in relapsed/refractory mantle cell lymphoma: A single-arm, multicenter, open-label, phase 2 study. Cancer, 127(10), 1617-1626.
[7] Byrd, J. C., & Woyach, J. A. (2018). Targeted inhibition of Bruton's tyrosine kinase in B-cell malignancies. New England Journal of Medicine, 379(3), 251-261.
[8] U.S. Food and Drug Administration. (n.d.). Cancer Approvals & Safety. Retrieved from https://www.fda.gov/drugs/new-drugs-fda-cders-drug-approvals/cancer-approvals-safety